Zacks: Analysts Expect Bausch Health Companies Inc (BHC) Will Announce Quarterly Sales of $2.09 Billion

Brokerages expect Bausch Health Companies Inc (NYSE:BHC) to report sales of $2.09 billion for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Bausch Health Companies’ earnings. The highest sales estimate is $2.21 billion and the lowest is $2.01 billion. Bausch Health Companies posted sales of $2.16 billion during the same quarter last year, which suggests a negative year over year growth rate of 3.2%. The company is scheduled to report its next quarterly earnings results on Wednesday, February 27th.

On average, analysts expect that Bausch Health Companies will report full-year sales of $8.34 billion for the current fiscal year, with estimates ranging from $8.27 billion to $8.47 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $8.50 billion, with estimates ranging from $8.30 billion to $8.81 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. Bausch Health Companies’s quarterly revenue was down 3.7% compared to the same quarter last year.

Several equities research analysts have issued reports on the company. Mizuho lifted their price objective on Bausch Health Companies from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, November 30th. BMO Capital Markets reiterated a “hold” rating and issued a $26.00 price target on shares of Bausch Health Companies in a report on Tuesday, November 13th. ValuEngine downgraded Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Monday, November 12th. TD Securities boosted their price target on Bausch Health Companies from $24.00 to $28.00 and gave the company a “hold” rating in a report on Wednesday, November 7th. Finally, Royal Bank of Canada boosted their price target on Bausch Health Companies from $30.00 to $31.00 and gave the company a “hold” rating in a report on Wednesday, November 7th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.18.

BHC stock traded down $0.59 during midday trading on Monday, hitting $23.66. 2,726,742 shares of the company’s stock were exchanged, compared to its average volume of 3,401,804. The company has a quick ratio of 0.91, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. Bausch Health Companies has a 12-month low of $14.44 and a 12-month high of $28.45. The company has a market capitalization of $8.48 billion, a PE ratio of 6.18, a P/E/G ratio of 0.32 and a beta of -0.28.

In related news, EVP Christina Ackermann sold 19,946 shares of the company’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total transaction of $498,251.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joseph C. Papa acquired 30,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 165,000 shares of company stock valued at $3,890,700. 11.54% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. NEXT Financial Group Inc bought a new position in Bausch Health Companies during the 3rd quarter worth $101,000. Steward Partners Investment Advisory LLC bought a new position in Bausch Health Companies during the 3rd quarter worth $106,000. Polaris Greystone Financial Group LLC bought a new position in Bausch Health Companies during the 3rd quarter worth $107,000. Quadrant Capital Group LLC bought a new position in Bausch Health Companies during the 3rd quarter worth $118,000. Finally, Bedel Financial Consulting Inc. bought a new position in Bausch Health Companies during the 3rd quarter worth $129,000. Hedge funds and other institutional investors own 50.09% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

See Also: Diversification

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply